In the News

Press Releases and Media Coverage

June 9, 2025

OncoLife: Targeting the “Don’t Eat Me Signal,” The Future of Macrophage Checkpoint Inhibitors in Oncology

Read Article
June 3, 2025

Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer

Read Article
April 14, 2025

Pheast Therapeutics Announces First Patient Treated in Phase 1 Clinical Trial of PHST001 for Patients with Advanced Solid Tumors

Read Article
February 18, 2025

Pheast Appoints Dr. Raphaël Rousseau as Chief Medical Officer

Read Article
December 2, 2024

The Bio Report Podcast: Getting Tumors to Say “Eat Me”

Read Article
November 8, 2024

The Cancer Letter: Preclinical Data Show Anti-CD24 Macrophage Checkpoint Inhibitor Promotes Phagocytosis and Shrinks Tumors

Read Article
November 7, 2024

Pheast Presents New Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor, at SITC 2024

Read Article
November 6, 2024

GEN: Parallel Platform Approach Slashes Process Development Time

Read Article
September 3, 2024

Drug Discovery Online: Does Targeting Macrophages Hold The Key For Treating Cancer?

Read Article
July 31, 2024

Cancer Research: Attacking Cancer Through Activating “Big Eaters” of the Immune System

Read Article